{
    "organizations": [],
    "uuid": "adc41103c87cd6ce5559c7d3ffa1db0586c16fb2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-morphosys-announces-approval-of-tr/brief-morphosys-announces-approval-of-tremfyain-south-korea-idUSFWN1S31QB",
    "ord_in_thread": 0,
    "title": "MorphoSys Announces Approval Of Tremfya(R)In South Korea",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 26 (Reuters) - MorphoSys AG:\n* DGAP-NEWS: MORPHOSYS ANNOUNCES APPROVAL OF TREMFYA(R) (GUSELKUMAB) IN SOUTH KOREA\n* MORPHOSYS IS ELIGIBLE TO RECEIVE ROYALTIES ON NET SALES OF TREMFYA\n* AFFILIATE OF ITS LICENSEE, JANSSEN KOREA REPORTED THAT SOUTH KOREAâ€™S MINISTRY OF FOOD AND DRUG SAFETY HAS APPROVED TREMFYA Source text for Eikon:\n ",
    "published": "2018-04-27T04:06:00.000+03:00",
    "crawled": "2018-04-27T16:46:18.035+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "morphosys",
        "ag",
        "morphosys",
        "announces",
        "approval",
        "tremfya",
        "r",
        "guselkumab",
        "south",
        "korea",
        "morphosys",
        "eligible",
        "receive",
        "royalty",
        "net",
        "sale",
        "tremfya",
        "affiliate",
        "licensee",
        "janssen",
        "korea",
        "reported",
        "south",
        "korea",
        "ministry",
        "food",
        "drug",
        "safety",
        "approved",
        "tremfya",
        "source",
        "text",
        "eikon"
    ]
}